Nikhil Prasad Fact checked by:Thailand Medical News Team May 18, 2026 45 minutes ago
Medical News: A decades-old drug commonly used to treat gout may soon find a surprising new role in the fight against some of the world’s deadliest viruses. Researchers have discovered that probenecid, a medication that has been safely used for more than 70 years, was able to strongly block the replication of Ebola and related filoviruses in laboratory experiments.
S
cientists discover that the common gout drug probenecid may help block Ebola, Sudan, and Marburg viruses in laboratory studies
The study was conducted by scientists from the Texas Biomedical Research Institute in San Antonio, the University of Georgia, Battelle Biomedical Research Center in Ohio, and TrippBio Inc. in Florida. Researchers also collaborated with experts linked to the Wisconsin National Primate Research Center.
Filoviruses include Ebola virus (EBOV), Sudan virus (SUDV), and Marburg virus (MARV), all of which can cause severe hemorrhagic fever with fatality rates that sometimes reach as high as 90 percent. While vaccines and treatments exist for certain Ebola strains, there are still no approved therapies for Sudan virus or Marburg virus infections.
Drug Reduced Virus Replication Dramatically
The research team tested probenecid in infected Vero E6 cells, which are laboratory-grown cells commonly used to study dangerous viruses. The scientists exposed the cells to Ebola, Sudan, and Marburg viruses and then treated them with varying concentrations of the drug.
The results were striking. At the highest concentrations, probenecid completely stopped viral plaque formation for all three viruses. Viral plaques are damaged areas in cells caused by virus spread, and fewer plaques indicate weaker viral activity.
Ebola virus appeared to be the most sensitive to the treatment. The drug achieved a 50 percent reduction in Ebola virus replication at only 3 micromolar concentration. For Marburg virus, the IC50 value was 8 micromolar, while Sudan virus required 13 micromolar.
Researchers also noticed that plaques became much smaller after treatment. Smaller plaques suggest the viruses were less able to spread from cell to cell, an important sign that the drug may interfere with the infection process itself.
Images from the experiments showed dramatic differences between treated and untreated samples. In Ebola-infected cells exposed to higher drug doses, plaques became extremely tiny compared to the larger destructive plaques seen in untreated cells.
Why Scientists Are Excited
Unlike many antiviral drugs that directly attack viruses, probenecid works by targeting processes inside host cells that viruses rely on to reproduce. This approach is known as “host-directed antiviral therapy.”
Scientists believe this strategy may offer major advantages. Viruses frequently mutate and become resistant to direct antiviral drugs. However, targeting stable human cellular pathways may make it harder for viruses to escape treatment.
Previous studies have already shown that probenecid can inhibit several respiratory viruses including influenza, SARS-CoV-2, respiratory syncytial virus, and human metapneumovirus.
This
f="https://www.thailandmedical.news/">Medical News report highlights that probenecid may also reduce harmful inflammation linked to severe viral infections. Researchers noted that the drug affects MAPK signaling pathways and the NLRP3 inflammasome, both of which are involved in viral replication and excessive immune responses.
Important Limitations Remain
Although the findings are encouraging, the scientists stressed that the experiments were performed only in laboratory cell cultures under high-containment Biosafety Level 4 conditions.
More research using animal models and eventually human clinical trials will be necessary before probenecid could be considered a real treatment option for Ebola or Marburg infections.
Still, the researchers believe the drug has several important advantages. It is already FDA-approved, inexpensive, widely available, and has a well-established safety history. These factors could speed up future development if additional studies confirm its effectiveness.
The team also suggested that probenecid might work even better when combined with other antiviral drugs such as remdesivir or obeldesivir, both of which target viral RNA replication directly.
Conclusion
The study offers fresh hope that an old and familiar medication could become part of the global defense against deadly filoviruses. Probenecid not only reduced Ebola, Sudan, and Marburg virus replication in laboratory cells, but also appeared to limit viral spread by shrinking plaque size. Because the drug targets host cellular pathways instead of the virus itself, researchers believe it may provide broad-spectrum protection that remains effective even as viruses evolve. While much more testing is still required, the findings open the door to a potentially affordable and widely accessible antiviral strategy for future outbreaks.
The study findings were published in the peer reviewed journal: Viruses.
https://www.mdpi.com/1999-4915/18/1/43
For the latest on Ebola, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/the-phytochemical-kolaviron-from-garcinia-kola-bitter-kola-shows-potential-against-the-ebola-virus-further-studies-needed
https://www.thailandmedical.news/news/study-finds-that-berberine-hydrochloride-could-be-used-to-inhibit-ebola-virus
https://www.thailandmedical.news/news/u-s-nih-study-finds-that-algal-lectin-griffithsin-shows-promise-in-preventing-ebola-virus-infection
Medical Disclaimer: All content published by Thailand Medical News is based on scientific research and is intended for informational and educational purposes only. It is not medical advice, diagnosis, or treatment. Readers must not attempt to use, apply, or experiment with any protocols, compounds, or therapies mentioned without first consulting a qualified and licensed medical doctor. Many findings discussed are experimental or preliminary, and only a licensed healthcare professional can determine what is safe and appropriate for an individual’s specific medical condition.
Share
Tweet
Share
